Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to
see how well they work in treating patients with malignant brain tumors that have come back
or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving ribociclib and
everolimus may work better at treating malignant brain tumors.